Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Tebentafusp
Synonyms
Therapy Description

Kimmtrak (tebentafusp) is a gp100 antigen-specific human T-cell receptor (TCR) linked to an anti-CD3 antibody fragment, which activates cytotoxic immune response against gp100-expressing tumor cells (PMID: 24531387, PMID: 31336704, PMID: 32816891). Kimmtrak (tebentafusp) is FDA approved for use in HLA-A*2:01-positive metastatic or unresectable uveal melanoma patients (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tebentafusp Kimmtrak ImmTAC-gp100|Tebentafusp-tebn|IMCgp100 Kimmtrak (tebentafusp) is a gp100 antigen-specific human T-cell receptor (TCR) linked to an anti-CD3 antibody fragment, which activates cytotoxic immune response against gp100-expressing tumor cells (PMID: 24531387, PMID: 31336704, PMID: 32816891). Kimmtrak (tebentafusp) is FDA approved for use in HLA-A*2:01-positive metastatic or unresectable uveal melanoma patients (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02570308 Phase I Tebentafusp A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Completed USA | GBR | ESP | DEU | CAN 0
NCT06246149 Phase III Tebentafusp Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) Recruiting POL | NLD | FRA | ESP | DEU | BEL 0
NCT06626516 Phase Ib/II Tebentafusp Sargramostim + Tebentafusp Carmustine + Tebentafusp Tebentafusp-tebn With LDT in Metastatic UM Recruiting USA 0
NCT06942442 Phase II Tebentafusp A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma Recruiting USA 0
NCT02535078 Phase Ib/II Durvalumab Tebentafusp Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Withdrawn USA 0
NCT05549297 Phase III Pembrolizumab + Tebentafusp Tebentafusp Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS 0
NCT06070012 Phase II Tebentafusp Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma Recruiting USA 0
NCT06414590 Phase II Tebentafusp Neoadjuvant Tebentafusp for Uveal Melanoma Recruiting USA 0
NCT07057596 Phase II Tebentafusp Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma (NEO-TB) Recruiting ESP | DEU 0
NCT02889861 Phase Ib/II Tebentafusp IMCgp100-401 Rollover Study Terminated USA | GBR 0
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab Tebentafusp Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 2
NCT06627244 Phase II Tebentafusp Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma Recruiting USA 0
NCT05315258 Phase II Tebentafusp Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Active, not recruiting GBR 0


Additional content available in Icon for CKB-BoostCKB BOOST